2Jordana P, Carmo -Fonsecab M. Molecular mechanisms involved in cisplatin cytotoxicity[ J]. Cell and Mol Life Sci,2000,57:1229 - 1235.
3Maurie Markman. New, expanded, and modified use of approved antineoplastic gents in ovarian cancer[ J]. Oncologist, 2007,12: 186 - 190.
4Pier Luigi Zorat, Adriano Paeeagnella, Gianearlo Cavaniglia. Randomized phase Ⅲ trial of neoadjuvant chemotherapy in head and neck cancer: 10 - year follow - up[J]. J Natl Cancer Institute, 2004 ,96(22) :1647 - 1649.
5Christensen TB, Daugaard G, Geertsen PF, et al. Effect of chemotherapy on carcinoma in situ of the testis[J].Ann Oncol, 1998 , 9(6) :657 -660.
6Strumberg D, Brugge S, Korn MW, et al. Evaluation of long - term toxicity in patients after cisplatin - based chemotherapy for non - seminomatous testicular cancer [ J ]. Annals of Oncol, 2002,13 : 229 - 236.
7Gholam D, Fizazi K,Terrier-Lacombe MJ. Advanced seminoma- treatment results and prognostic factors for survival after first - line, cisplatin -based chemotherapy and for patients with recurrent disease : a single - institution experience in 145 patients [ J ]. Cancer, 2003 ,98(4) :745 -752.
8Heather Wakelee, Chandra P Belani. Optimizing first - line treatment options for patients with advanced NSCLC [ J ]. Oncologist, 2005,10:1 - 10.
9Abratt RP, Hart GJ. 10 -year update on chemotherapy for non - small cell lung cancer [ J ]. Ann Oncol,2006,17 (Suppl 5 ) :33 - 36.
10Carvalho Junior AD, Vieiral FP, De Melo VJ. Preparation and cytotoxicity of cisplatin - containing liposomes [ J ]. Brazilian J Med and Biol Res ,2007, 40 : 1149 - 1157.
